THOMAS L HARRISON
CIK 1247340 · Chrmn/CEO Divers. Agency Serv. · last filed 2026-04-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.10M
Companies
12
Total Filings
53
Lifetime Open-Market Net
-$2.81M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AGEN | Director | 38,998 | $3.30 | $128.7K | $0 | 7 | 2026-04-28 |
| ACXP | Director | — | $1.57 | — | $0 | 4 | 2026-04-22 |
| AFCG | Director | 24,539 | $3.42 | $83.9K | $95.0K | 6 | 2025-11-24 |
| Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Director | 12,500 | $1.30 | $16.2K | $175.0K | 8 | 2018-06-07 |
| SBH | Director | 0 | $13.85 | $0 | -$187.1K | 5 | 2017-12-11 |
| PLx Pharma Inc. (PLXP) Delisted | Director | — | $0.09 | — | $0 | 1 | 2017-04-20 |
| Fifth Street Asset Management Inc. (FSAM) Delisted | Director | 6,000 | — | — | $102.0K | 4 | 2016-03-18 |
| PLx Pharma Inc. (DPRX) Delisted | Director | 148,832 | — | — | $24.0K | 3 | 2016-01-21 |
| EPOCRATES INC (EPOC) Delisted | Director | — | — | — | $0 | 3 | 2013-03-13 |
| Morgans Hotel Group Co. (MHGC) Delisted | Director | 41,269 | — | — | $0 | 5 | 2012-05-21 |
| OMNICOM GROUP INC. (OMCw) Delisted | Chrmn/CEO Divers. Agency Serv. | 199,149 | — | — | -$3.02M | 5 | 2010-03-31 |
| OMC | Chrmn/CEO Divers. Agency Serv. | 89,878 | $76.68 | $6.89M | $0 | 1 | 2007-03-29 |
Recent Filings · Page 2 of 6
53 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-18 | ACXP | Grant (A) | — | $0 | EDGAR |
| 2024-01-25 | AFCG | Grant (A) | +1,282 | $15.0K | EDGAR |
| 2023-06-16 | ACXP | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | AFCG | Grant (A) | +963 | $15.0K | EDGAR |
| 2022-01-13 | AFCG | Grant (A) | — | $0 | EDGAR |
| 2021-07-06 | ACXP | Grant (A) | — | $0 | EDGAR |
| 2021-03-25 | AFCG | Mixed | +5,000 | $95.0K | EDGAR |
| 2018-06-07 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-11 | SBH | Sell (S) | −6,000 | -$24.3K | EDGAR |
| 2017-12-11 | SBH | Mixed | — | -$15.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.